Trigo-Vicente, C., Gimeno-Ballester, V., & López-Del Val, A. (2020). Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm.
Dyfyniad Arddull ChicagoTrigo-Vicente, Cristina, Vicente Gimeno-Ballester, and Alejandro López-Del Val. "Cost-effectiveness Analysis of Infliximab, Adalimumab, Golimumab, Vedolizumab and Tofacitinib for Moderate to Severe Ulcerative Colitis in Spain." Eur J Hosp Pharm 2020.
Dyfyniad MLATrigo-Vicente, Cristina, Vicente Gimeno-Ballester, and Alejandro López-Del Val. "Cost-effectiveness Analysis of Infliximab, Adalimumab, Golimumab, Vedolizumab and Tofacitinib for Moderate to Severe Ulcerative Colitis in Spain." Eur J Hosp Pharm 2020.